Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Ashley D, Hadjis"'
Autor:
Ashley D. Hadjis, Shannon R. McCurdy
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
Allogeneic hematopoietic cell transplantation (HCT) has transformed over the past several decades through enhanced supportive care, reduced intensity conditioning (RIC), improved human leukocyte antigen (HLA) typing, and novel graft-versus-host disea
Externí odkaz:
https://doaj.org/article/e107391e9f654cecbd464890851c5fcd
Autor:
Ashley D. Hadjis, Natalia S. Nunes, Shanzay M. Khan, Rochelle E. Fletcher, Alessandra de Paula Pohl, David J. Venzon, Michael A. Eckhaus, Christopher G. Kanakry
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Post-transplantation cyclophosphamide (PTCy) reduces the incidence and severity of graft-versus-host disease (GVHD), thereby improving the safety and accessibility of allogeneic hematopoietic cell transplantation (HCT). We have shown that PTCy works
Externí odkaz:
https://doaj.org/article/2353e45dfe2c40c589b13c56dc2a4754
Autor:
Michael T. Patterson, Shanzay M. Khan, Natalia S. Nunes, Rochelle E. Fletcher, Jing Bian, Ashley D. Hadjis, Michael A. Eckhaus, Suresh K. Mendu, Alessandra de Paula Pohl, David J. Venzon, Hyoyoung Choo-Wosoba, Kazusa Ishii, Haiying Qin, Terry J. Fry, Maggie Cam, Christopher G. Kanakry
Publikováno v:
Blood. 141:659-672
Relapse limits the therapeutic efficacy both of chimeric antigen receptor (CAR) T cells and allogeneic hematopoietic cell transplantation (allo-HCT). Patients may undergo these therapies sequentially to prevent or treat relapsed malignancy. However,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c01008114de1005258e673a76ca91af4
https://doi.org/10.1182/blood.2022016660
https://doi.org/10.1182/blood.2022016660
Autor:
Ashley D, Hadjis, Natalia S, Nunes, Shanzay M, Khan, Rochelle E, Fletcher, Alessandra de Paula, Pohl, David J, Venzon, Michael A, Eckhaus, Christopher G, Kanakry
Publikováno v:
Frontiers in immunology. 13
Post-transplantation cyclophosphamide (PTCy) reduces the incidence and severity of graft-versus-host disease (GVHD), thereby improving the safety and accessibility of allogeneic hematopoietic cell transplantation (HCT). We have shown that PTCy works
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::100d2d4404b8c32346ecce6dd1e82297
https://pubmed.ncbi.nlm.nih.gov/35493453
https://pubmed.ncbi.nlm.nih.gov/35493453